This population-based cohort study analyzed 282,969 five-year survivors of adolescent and young adult (AYA) cancers diagnosed between 1975 and 2011, using SEER registry data. Over four decades, 5-year post-survival all-cause mortality decreased from 8.3% to 5.4%, primarily due to reductions in primary cancer mortality (6.8% to 4.2%). Significant improvements were
This 2023 expert commentary discusses the 15-year follow-up results of the ProtecT trial, which compared active monitoring, radical prostatectomy, and radiotherapy in men with localized prostate cancer. The trial found no statistically significant difference in prostate cancer-specific mortality among the three treatment modalities, with overall mortality remaining low across the
This retrospective cohort study analyzed long-term outcomes in breast cancer patients diagnosed using fine-needle aspiration biopsy (FNAB) in the 1970s versus core-needle biopsy (CNB) in the 1990s. Researchers matched patients on age, tumor size, DNA ploidy, mammography screening status, and treatment protocols. The findings indicated a significantly higher incidence of
This 2023 study evaluates the long-term surgical burden in survivors of childhood cancer using data from the CCSS cohort, comprising 25,656 survivors diagnosed between 1970–1999 and 5,045 sibling controls. Over a median follow-up of 21.8 years, survivors underwent 28,202 major surgical procedures (≥5 years post-diagnosis under anesthesia) versus 4,110 among
This randomized controlled trial (PMID: 36912538) followed 1643 men aged 50-69 years with localized prostate cancer over 15 years, comparing outcomes of active monitoring, surgery, and radiotherapy. Prostate cancer-specific mortality was low across all groups (3.1%) with no significant difference between treatments, but active monitoring had higher rates of progression
This 2019 prospective cohort study published in JAMA Network Open (PMID: 31390038) analyzed long-term immune response trajectories in 483 sepsis survivors across 12 U.S. hospitals. Researchers tracked biomarkers of inflammation (hs-CRP) and immunosuppression (sPD-L1) over 12 months and identified two phenotypes: one with persistent hyperinflammation and immunosuppression, and another with
This randomized controlled trial evaluated the long-term outcomes of monitoring, surgery, or radiotherapy in patients with localized prostate cancer. Over a 10-year period, the study found no significant differences in prostate cancer-specific mortality between the three treatment groups. However, surgery and radiotherapy were associated with higher rates of erectile dysfunction
The commentary discusses the long-term quality of life outcomes in prostate cancer patients, referencing the Prostate Cancer Outcomes Study (PCOS), which followed 1,655 men aged 55-74 years over 15 years. The study found significant declines in sexual, urinary, and bowel function across all treatment modalities. Erectile dysfunction was prevalent in
This randomized controlled trial examined long-term quality-of-life outcomes in 400 Swedish and Finnish men with localized prostate cancer randomized to either radical prostatectomy or watchful waiting, with a median follow-up of 12.2 years. Self-assessed high quality of life was reported by 35% in the prostatectomy group, 34% in the watchful
This meta-analysis evaluated the 10-year outcomes of the TROG 03.04 RADAR trial, which compared 6 months versus 18 months of androgen suppression (AS) combined with radiotherapy (RT), with or without zoledronic acid (ZA), in men with locally advanced prostate cancer. The study found that extending AS to 18 months significantly
